Jefferies Group Weighs in on Marrone Bio Innovations Inc’s FY2022 Earnings (MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) – Research analysts at Jefferies Group issued their FY2022 earnings per share estimates for Marrone Bio Innovations in a research report issued to clients and investors on Thursday. Jefferies Group analyst L. Alexander expects that the basic materials company will earn $0.03 per share for the year.

Marrone Bio Innovations (NASDAQ:MBII) last released its earnings results on Monday, November 13th. The basic materials company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.03). The business had revenue of $4.22 million during the quarter, compared to analyst estimates of $5.32 million.

MBII has been the topic of several other reports. ValuEngine raised Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright set a $4.00 target price on Marrone Bio Innovations and gave the stock a “buy” rating in a report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $2.50.

Marrone Bio Innovations (NASDAQ:MBII) traded up $0.06 during trading on Friday, reaching $1.24. The company’s stock had a trading volume of 145,525 shares, compared to its average volume of 102,608. The company has a quick ratio of 0.36, a current ratio of 0.69 and a debt-to-equity ratio of -1.14. Marrone Bio Innovations has a twelve month low of $0.85 and a twelve month high of $2.30. The company has a market capitalization of $36.99, a P/E ratio of -1.03 and a beta of 0.26.

In other Marrone Bio Innovations news, insider Ardsley Advisory Partners purchased 6,666,667 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was purchased at an average price of $0.75 per share, for a total transaction of $5,000,000.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.80% of the stock is owned by insiders.

An institutional investor recently raised its position in Marrone Bio Innovations stock. Ardsley Advisory Partners lifted its holdings in Marrone Bio Innovations Inc (NASDAQ:MBII) by 375.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,681,580 shares of the basic materials company’s stock after purchasing an additional 2,907,142 shares during the quarter. Ardsley Advisory Partners owned 11.74% of Marrone Bio Innovations worth $4,528,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 37.59% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/09/jefferies-group-weighs-in-on-marrone-bio-innovations-incs-fy2022-earnings-mbii.html.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit